维持治疗的分子靶标作用.pptVIP

* * Methodology CONFIRM anti-total Met, as per manufacturer’s instructions Run on Ventana Benchmark instrument at GNE Negative controls (isotype control) performed on each specimen Positive controls (cell pellets) included on every run * * * * Philip C. Mack, PhD Associate Adjunct Professor UC Davis Cancer Center How do we perform more effective biomarker testing for matching NSCLC patients with optimal therapy for maintenance of disease remission and after relapsed NSCLC?? A patient has benefited from treatment (tumor response or durable stable disease) How can we use biomarkers to help: